Bioregulator peptides

16 peptides tagged bioregulator. Each page carries the dosing reference, mechanism, evidence grade and references.

PeptideLab is an educational platform for learning about peptides. The information here is for educational and research purposes only. It is not medical advice, diagnosis, or treatment, and PeptideLab does not claim to diagnose, treat, cure, or prevent any disease or health condition. Many peptides discussed have not been approved for human use by the FDA or other regulatory bodies. Consult a qualified healthcare professional before making any health-related decision.

  • Bronchogen

    Khavinson-series synthetic tetrapeptide (AEDL) for bronchial tissue; reported to restore bronchial epithelium in a rat NO2 model of COPD and to drive bronchial cell differentiation in vitro.

    Evidence: Preclinical

  • Cardiogen

    Khavinson-series synthetic tetrapeptide (AEDR) for heart tissue; studied in rat myocardial explants and mouse fibroblasts, where it raised proliferation and cytoskeletal proteins.

    Evidence: Preclinical

  • Cartalax

    Khavinson-series synthetic tripeptide (AED) for cartilage; in vitro it raised chondrogenic markers in aging human stem cells and reduced senescence markers in chondrocytes.

    Evidence: Preclinical

  • Chonluten

    Khavinson-series synthetic tripeptide (EDG) assigned to bronchial tissue; in vitro it suppressed LPS-induced TNF release by human monocytes. No controlled human trial.

    Evidence: Preclinical

  • Cortagen

    Khavinson-series synthetic tetrapeptide (AEDP) designed from the brain extract Cortexin; studied in rats for sciatic nerve regeneration and in rodent brain for antioxidant effects.

    Evidence: Preclinical

  • Livagen

    Khavinson-series synthetic tetrapeptide (KEDA) designed from liver peptide preparations; studied mainly in cultured lymphocytes from elderly donors and in rat hepatocytes.

    Evidence: Preclinical

  • Ovagen

    Khavinson-series synthetic tripeptide (EDL); despite the name, its published work is on kidney: it protected rat kidneys in toxic and ischemic injury models.

    Evidence: Preclinical

  • Pancragen

    Khavinson-series synthetic tetrapeptide (KEDW-NH2) for pancreas; improved glucose tolerance in old rhesus monkeys and diabetic rats, plus one small human study against untreated controls.

    Evidence: Preclinical

  • Pinealon

    Khavinson-series synthetic tripeptide (EDR) from the brain drug Cortexin; protected neurons from oxidative stress in vitro and in rats, and preserved dendritic spines in Alzheimer model mice.

    Evidence: Preclinical

  • Prostamax

    Khavinson-series synthetic tetrapeptide (KEDP) assigned to prostate; published work is limited to chromatin effects in lymphocytes from elderly donors and one rat explant study.

    Evidence: Preclinical

  • Testagen

    Khavinson-series synthetic tetrapeptide KEDG (Lys-Glu-Asp-Gly), described as pituitary-derived; studied for thyroid and thymus effects in hypophysectomized chickens. No testis study exists.

    Evidence: Preclinical

  • Thymagen

    Synthetic dipeptide EW (Glu-Trp), registered in Russia as Timogen; tested in the US as IM862 (oglufanide), where a phase III trial in AIDS-related Kaposi sarcoma found no benefit over placebo.

    Evidence: Clinical

  • Thymalin

    Peptide extract of calf thymus, registered in Russia as a 10 mg injectable lyophilizate; its developers tested it as add-on therapy for COVID-19 in an open-label randomized trial (n=92).

    Evidence: Clinical

  • Vesilute

    Synthetic dipeptide ED (Glu-Asp), listed by its developers as Vesilut; it appears only in transporter docking studies, and no published study supports its bladder label.

    Evidence: Anecdotal

  • Vesugen

    Khavinson-series synthetic tripeptide KED (Lys-Glu-Asp), sold as a vascular bioregulator; studied in endothelial cell cultures and a mouse Alzheimer model, with uncontrolled Russian human reports.

    Evidence: Preclinical

  • Vilon

    Khavinson-series synthetic dipeptide KE (Lys-Glu); in rodents it slowed induced bladder tumours but did not extend mouse lifespan, and it reactivated chromatin in lymphocytes from older donors.

    Evidence: Preclinical

Other categories